{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:28:23Z","timestamp":1777577303453,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority","award":["HHSO100201600015C"],"award-info":[{"award-number":["HHSO100201600015C"]}]},{"name":"Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority","award":["HHSO100201600015C"],"award-info":[{"award-number":["HHSO100201600015C"]}]},{"name":"Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority","award":["HHSO100201600015C"],"award-info":[{"award-number":["HHSO100201600015C"]}]},{"name":"Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority","award":["HHSO100201600015C"],"award-info":[{"award-number":["HHSO100201600015C"]}]},{"name":"Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority","award":["HHSO100201600015C"],"award-info":[{"award-number":["HHSO100201600015C"]}]},{"name":"Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority","award":["HHSO100201600015C"],"award-info":[{"award-number":["HHSO100201600015C"]}]},{"name":"Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority","award":["HHSO100201600015C"],"award-info":[{"award-number":["HHSO100201600015C"]}]},{"name":"Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority","award":["HHSO100201600015C"],"award-info":[{"award-number":["HHSO100201600015C"]}]},{"name":"Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority","award":["HHSO100201600015C"],"award-info":[{"award-number":["HHSO100201600015C"]}]},{"name":"Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority","award":["HHSO100201600015C"],"award-info":[{"award-number":["HHSO100201600015C"]}]},{"name":"Takeda Vaccines, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A critical global health need exists for a Zika vaccine capable of mitigating the effects of future Zika epidemics. In this study we evaluated the antibody responses and efficacy of an aluminum hydroxide adjuvanted purified inactivated Zika vaccine (PIZV) against challenge with Zika virus (ZIKV) strain PRVABC59. Indian rhesus macaques received two doses of PIZV at varying concentrations ranging from 0.016\u2009\u00b5g \u2212 10\u2009\u00b5g and were subsequently challenged with ZIKV six weeks or one year following the second immunization. PIZV induced a dose-dependent immune response that was boosted by a second immunization. Complete protection against ZIKV infection was achieved with the higher PIZV doses of 0.4\u2009\u00b5g, 2\u2009\u00b5g, and 10\u2009\u00b5g at 6 weeks and \u00a0with 10 ug PIZV\u00a0at \u00a01 year following vaccination. Partial protection was achieved with the lower PIZV doses of 0.016\u2009\u00b5g and 0.08\u2009\u00b5g. Based on these data, a neutralizing antibody response above 3.02 log<jats:sub>10<\/jats:sub> EC50 was determined as a correlate of protection in macaques. PIZV elicited a dose-dependent neutralizing antibody response which is protective for at least 1 year following vaccination.<\/jats:p>","DOI":"10.1038\/s41598-020-60415-6","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T11:03:14Z","timestamp":1582714994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Complete Protection in Macaques Conferred by Purified Inactivated Zika Vaccine: Defining a Correlate of Protection"],"prefix":"10.1038","volume":"10","author":[{"given":"Ginger","family":"Young","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly J.","family":"Bohning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Zahralban-Steele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Hather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sambasivarao","family":"Tadepalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Mickey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Steven","family":"Godin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srisowmya","family":"Sanisetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Sonnberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hetal K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansi J.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,26]]},"reference":[{"key":"60415_CR1","doi-asserted-by":"publisher","first-page":"858","DOI":"10.15585\/mmwr.mm6731e1","volume":"67","author":"ME Rice","year":"2018","unstructured":"Rice, M. E. et al. Vital Signs: Zika-Associated Birth Defects and Neurodevelopmental Abnormalities Possibly Associated with Congenital Zika Virus Infection - U.S. Territories and Freely Associated States, 2018. MMWR Morb. Mortal. Wkly. Rep. 67, 858\u2013867, https:\/\/doi.org\/10.15585\/mmwr.mm6731e1 (2018).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"60415_CR2","unstructured":"WHO Region of the Americas\/Pan American Health Organization. PLISA Health Information Platform for the Americas: Cases of Zika virus disease, by country or territory, http:\/\/www.paho.org\/data\/index.php\/en\/mnu-topics\/zika\/524-zika-weekly-en.html (Accessed 27Aug2019)."},{"key":"60415_CR3","doi-asserted-by":"publisher","first-page":"S964","DOI":"10.1093\/infdis\/jix433","volume":"216","author":"MF Gruber","year":"2017","unstructured":"Gruber, M. F. et al. Clinical Development Strategies and Considerations for Zika Vaccine Licensure. J. Infect. Dis. 216, S964\u2013S970, https:\/\/doi.org\/10.1093\/infdis\/jix433 (2017).","journal-title":"J. Infect. Dis."},{"key":"60415_CR4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17, 1055\u20131065, https:\/\/doi.org\/10.1128\/CVI.00131-10 (2010).","journal-title":"Clin. Vaccine Immunol."},{"key":"60415_CR5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.vaccine.2018.12.040","volume":"37","author":"KS Vannice","year":"2019","unstructured":"Vannice, K. S. et al. Demonstrating vaccine effectiveness during a waning epidemic: A WHO\/NIH meeting report on approaches to development and licensure of Zika vaccine candidates. Vaccine 37, 863\u2013868, https:\/\/doi.org\/10.1016\/j.vaccine.2018.12.040 (2019).","journal-title":"Vaccine"},{"key":"60415_CR6","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.aah6157","volume":"353","author":"P Abbink","year":"2016","unstructured":"Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Sci. 353, 1129\u20131132, https:\/\/doi.org\/10.1126\/science.aah6157 (2016).","journal-title":"Sci."},{"key":"60415_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1126\/science.aai9137","volume":"354","author":"KA Dowd","year":"2016","unstructured":"Dowd, K. A. et al. Rapid development of a DNA vaccine for Zika virus. Sci. 354, 237\u2013240, https:\/\/doi.org\/10.1126\/science.aai9137 (2016).","journal-title":"Sci."},{"key":"60415_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2017.03.016","volume":"169","author":"JM Richner","year":"2017","unstructured":"Richner, J. M. et al. Modified mRNA Vaccines Protect against Zika Virus Infection. Cell 169, 176, https:\/\/doi.org\/10.1016\/j.cell.2017.03.016 (2017).","journal-title":"Cell"},{"issue":"5","key":"60415_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/v10050229","volume":"10","author":"Jonathan Rayner","year":"2018","unstructured":"Rayner, J. O. et al. Comparative Pathogenesis of Asian and African-Lineage Zika Virus in Indian Rhesus Macaque\u2019s and Development of a Non-Human Primate Model Suitable for the Evaluation of New Drugs and Vaccines. Viruses 10, https:\/\/doi.org\/10.3390\/v10050229 (2018).","journal-title":"Viruses"},{"key":"60415_CR10","doi-asserted-by":"publisher","first-page":"S928","DOI":"10.1093\/infdis\/jix540","volume":"216","author":"CE Osuna","year":"2017","unstructured":"Osuna, C. E. & Whitney, J. B. Nonhuman Primate Models of Zika Virus Infection, Immunity, and Therapeutic Development. J. Infect. Dis. 216, S928\u2013S934, https:\/\/doi.org\/10.1093\/infdis\/jix540 (2017).","journal-title":"J. Infect. Dis."},{"key":"60415_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.coviro.2017.06.011","volume":"25","author":"C Newman","year":"2017","unstructured":"Newman, C., Friedrich, T. C. & O\u2019Connor, D. H. Macaque monkeys in Zika virus research: 1947-present. Curr. Opin. Virol. 25, 34\u201340, https:\/\/doi.org\/10.1016\/j.coviro.2017.06.011 (2017).","journal-title":"Curr. Opin. Virol."},{"key":"60415_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ebiom.2016.09.022","volume":"12","author":"XF Li","year":"2016","unstructured":"Li, X. F. et al. Characterization of a 2016 Clinical Isolate of Zika Virus in Non-human Primates. EBioMedicine 12, 170\u2013177, https:\/\/doi.org\/10.1016\/j.ebiom.2016.09.022 (2016).","journal-title":"EBioMedicine"},{"key":"60415_CR13","doi-asserted-by":"publisher","first-page":"e0005168","DOI":"10.1371\/journal.pntd.0005168","volume":"10","author":"MT Aliota","year":"2016","unstructured":"Aliota, M. T. et al. Heterologous Protection against Asian Zika Virus Challenge in Rhesus Macaques. PLoS Negl. Trop. Dis. 10, e0005168, https:\/\/doi.org\/10.1371\/journal.pntd.0005168 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"60415_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12204","volume":"7","author":"DM Dudley","year":"2016","unstructured":"Dudley, D. M. et al. A rhesus macaque model of Asian-lineage Zika virus infection. Nat. Commun. 7, 12204, https:\/\/doi.org\/10.1038\/ncomms12204 (2016).","journal-title":"Nat. Commun."},{"key":"60415_CR15","doi-asserted-by":"publisher","first-page":"e1006219","DOI":"10.1371\/journal.ppat.1006219","volume":"13","author":"AJ Hirsch","year":"2017","unstructured":"Hirsch, A. J. et al. Zika Virus infection of rhesus macaques leads to viral persistence in multiple tissues. PLoS Pathog. 13, e1006219, https:\/\/doi.org\/10.1371\/journal.ppat.1006219 (2017).","journal-title":"PLoS Pathog."},{"key":"60415_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34735-7","volume":"8","author":"WR Baldwin","year":"2018","unstructured":"Baldwin, W. R. et al. Purified Inactivated Zika Vaccine Candidates Afford Protection against Lethal Challenge in Mice. Sci. Rep. 8, 16509, https:\/\/doi.org\/10.1038\/s41598-018-34735-7 (2018).","journal-title":"Sci. Rep."},{"key":"60415_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep46375","volume":"7","author":"K Sumathy","year":"2017","unstructured":"Sumathy, K. et al. Protective efficacy of Zika vaccine in AG129 mouse model. Sci. Rep. 7, 46375, https:\/\/doi.org\/10.1038\/srep46375 (2017).","journal-title":"Sci. Rep."},{"key":"60415_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","volume":"543","author":"N Pardi","year":"2017","unstructured":"Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nat. 543, 248\u2013251, https:\/\/doi.org\/10.1038\/nature21428 (2017).","journal-title":"Nat."},{"key":"60415_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/npjvaccines.2016.21","volume":"1","author":"K Muthumani","year":"2016","unstructured":"Muthumani, K. et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. NPJ Vaccines 1, 16021, https:\/\/doi.org\/10.1038\/npjvaccines.2016.21 (2016).","journal-title":"NPJ Vaccines"},{"key":"60415_CR20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature18952","volume":"536","author":"RA Larocca","year":"2016","unstructured":"Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nat. 536, 474\u2013478, https:\/\/doi.org\/10.1038\/nature18952 (2016).","journal-title":"Nat."},{"issue":"420","key":"60415_CR21","doi-asserted-by":"publisher","first-page":"eaao4163","DOI":"10.1126\/scitranslmed.aao4163","volume":"9","author":"Peter Abbink","year":"2017","unstructured":"Abbink, P. et al. Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Sci Transl Med 9, https:\/\/doi.org\/10.1126\/scitranslmed.aao4163 (2017).","journal-title":"Science Translational Medicine"},{"key":"60415_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ebiom.2017.12.010","volume":"27","author":"D Espinosa","year":"2018","unstructured":"Espinosa, D. et al. Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge. EBioMedicine 27, 61\u201370, https:\/\/doi.org\/10.1016\/j.ebiom.2017.12.010 (2018).","journal-title":"EBioMedicine"},{"key":"60415_CR23","doi-asserted-by":"publisher","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","volume":"23","author":"J Hombach","year":"2005","unstructured":"Hombach, J., Solomon, T., Kurane, I., Jacobson, J. & Wood, D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 23, 5205\u20135211, https:\/\/doi.org\/10.1016\/j.vaccine.2005.07.002 (2005).","journal-title":"Vaccine"},{"key":"60415_CR24","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1128\/AEM.25.4.539-544.1973","volume":"25","author":"RA Mason","year":"1973","unstructured":"Mason, R. A., Tauraso, N. M., Spertzel, R. O. & Ginn, R. K. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl. Microbiol. 25, 539\u2013544 (1973).","journal-title":"Appl. Microbiol."},{"key":"60415_CR25","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1128\/JVI.72.4.3076-3081.1998","volume":"72","author":"TR Kreil","year":"1998","unstructured":"Kreil, T. R., Maier, E., Fraiss, S. & Eibl, M. M. Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein. J. Virol. 72, 3076\u20133081 (1998).","journal-title":"J. Virol."},{"key":"60415_CR26","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(17)33106-9","volume":"391","author":"K Modjarrad","year":"2018","unstructured":"Modjarrad, K. et al. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet 391, 563\u2013571, https:\/\/doi.org\/10.1016\/S0140-6736(17)33106-9 (2018).","journal-title":"Lancet"},{"issue":"1","key":"60415_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/v11010029","volume":"11","author":"Loulieta Nazerai","year":"2019","unstructured":"Nazerai, L., Pravsgaard Christensen, J. & Randrup Thomsen, A. A \u2018Furry-Tale\u2019 of Zika Virus Infection: What Have We Learned from Animal Models? Viruses 11, https:\/\/doi.org\/10.3390\/v11010029 (2019).","journal-title":"Viruses"},{"key":"60415_CR28","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3201\/eid2205.160065","volume":"22","author":"RS Lanciotti","year":"2016","unstructured":"Lanciotti, R. S., Lambert, A. J., Holodniy, M., Saavedra, S. & Signor Ldel, C. Phylogeny of Zika Virus in Western Hemisphere, 2015. Emerg. Infect. Dis. 22, 933\u2013935, https:\/\/doi.org\/10.3201\/eid2205.160065 (2016).","journal-title":"Emerg. Infect. Dis."},{"key":"60415_CR29","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.celrep.2016.07.049","volume":"16","author":"KA Dowd","year":"2016","unstructured":"Dowd, K. A. et al. Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. Cell Rep. 16, 1485\u20131491, https:\/\/doi.org\/10.1016\/j.celrep.2016.07.049 (2016).","journal-title":"Cell Rep."},{"key":"60415_CR30","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.tim.2017.10.004","volume":"26","author":"CA Sariol","year":"2018","unstructured":"Sariol, C. A., Nogueira, M. L. & Vasilakis, N. A Tale of Two Viruses: Does Heterologous Flavivirus Immunity Enhance Zika Disease? Trends Microbiol. 26, 186\u2013190, https:\/\/doi.org\/10.1016\/j.tim.2017.10.004 (2018).","journal-title":"Trends Microbiol."},{"key":"60415_CR31","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/nm.4206","volume":"22","author":"CE Osuna","year":"2016","unstructured":"Osuna, C. E. et al. Zika viral dynamics and shedding in rhesus and cynomolgus macaques. Nat. Med. 22, 1448\u20131455, https:\/\/doi.org\/10.1038\/nm.4206 (2016).","journal-title":"Nat. Med."},{"issue":"4","key":"60415_CR32","doi-asserted-by":"publisher","first-page":"a028902","DOI":"10.1101\/cshperspect.a028902","volume":"10","author":"Hana Golding","year":"2017","unstructured":"Golding, H., Khurana, S. & Zaitseva, M. What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection. Cold Spring Harb Perspect Biol 10, https:\/\/doi.org\/10.1101\/cshperspect.a028902 (2018).","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"60415_CR33","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3201\/eid1408.080287","volume":"14","author":"RS Lanciotti","year":"2008","unstructured":"Lanciotti, R. S. et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg. Infect. Dis. 14, 1232\u20131239, https:\/\/doi.org\/10.3201\/eid1408.080287 (2008).","journal-title":"Emerg. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60415-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60415-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60415-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:37:58Z","timestamp":1670312278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60415-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,26]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["60415"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-60415-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,26]]},"assertion":[{"value":"17 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.Y., K.J.B., M.Z., G.H., S. Sonnberg, H.K.P. and H.J.D. are employees of Takeda. S. Sanisetty was a contract researcher on assignment with Takeda. S.T. works as an employee of Charles River Laboratories, contracted by Takeda. K.M. works as an employee of Viracor Eurofins, contracted by Takeda. C.S.G. works as an employee of Inotiv, contracted by Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3488"}}